,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['bcsm', 'destiny,breast,4', 'breast', 'destiny-breast04']
breaking #asco22 news: novel anti-body drug conjugate doubles progression-free survival in her2-low metastatic breast cancer. dr. modi breaks down some of the findings in the destiny-breast04 trial. #bcsm 
Scientist with 25 yrs' experience in Pharmaceutical R&D and Medical Communications.